Novartis is an international pharmaceutical company headquartered in Basel, Switzerland. Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 142 nationalities work at Novartis around the world.
Novartis Group in Russia offers healthcare solutions that meet the most urgent needs of society and patients. The history of the company has been conducted since the opening of the first pharmaceutical manufactory at the end of the XIX century and for almost a century and a half the company has been a reliable partner of the healthcare system in our country. The company develops research and educational activities in partnership with the leading universities and research institutes, implements various programs to improve the healthcare system, and conducts international and local clinical trials. Among the company’s key priorities is the development and provision of timely patient access to advanced therapeutic platforms that can transform approaches to the treatment of rare diseases, including gene and cell therapy.
Novartis has a diversified product portfolio and occupies leading positions in the Russian market in the production of innovative and replicated drugs. All Group’s divisions are currently presented in Russia – innovative products, generic pharmaceutical and biosimilars, own manufacturing site production in St. Petersburg – while the number of employees approaches 2,000.
Novartis Pharma is among leaders in the patented medicines development. Key areas of the company’s expertise are research, development and manufacture for such areas as cardiovascular, endocrinology, rheumatology, neurology, ophthalmology, transplantology, immunology and respiratory diseases. Today Novartis Pharma innovative medicines are available in 155 countries around the world. The company’s current portfolio also includes more than 30 new molecules at different stages of clinical development. The company is the leader in the number of clinical trials in Russia among foreign manufacturers.
A leading innovator in cancer research and care, providing patients with the access to the essential therapy. Novartis Oncology was allocated as a business division in 2016 upon the termination of merger with the GSK oncological portfolio. Today the unparalleled portfolio of Novartis Oncology includes more than 20 drugs on the market and more than 30 new molecular entities in development targeting key molecular pathways in cancer biology. 10- years strategy of the division is focused on obtaining leadership in five key therapeutic areas – breast, lung, liver, blood cancer and melanoma, and strives to fulfill key mission of Novartis Oncology business – to transform the way patients live with cancer and related diseases
Generic and biosimilar medicines
Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. In 2021 the company celebrates its 15th anniversary since the registration of the first biosimilar. The company has been operating in Russia for more than 25 years and according to the results of 2020 is one of the three leaders among generic companies on the Russian market. The product portfolio currently represented in Russia, includes more than 100 nonprescription, prescription and specialized drugs in 20 main therapeutic areas, including oncology, cardiology, gastroenterology, rheumatology, pulmonology and others.
Construction of Novartis Neva, Novartis’s own manufacturing site in St. Petersburg, was сompleted in June 2015. Novartis Neva is a modern site designed for the production of solid dosage forms. Commercial production started in 2017, followed by the first launch of the finished dosage form production (from the preparation of the finished dosage form to the release on the Russian market) happened in 2018. Currently, Neva produces an integrated portfolio of innovative medicine products and highquality generics of Novartis and Sandoz divisions for the Russian market. The main therapeutic areas of the products that are produced at Novartis Neva include cardiology, transplantology, pulmonology, neurology and endocrinology.
Novartis is reimagining medicine to improve and extend people’s lives. Novartis develops innovative
products for use in various fields of medicine and ranks among the world’s top companies investing in
research and development. The company uses latest scientific and technological platforms to solve
complex healthcare challenges. More than 769 million people globally receives Novartis products and the
company are finding innovative ways to expand access to latest treatments. More than 110,000 people of
more than 142 nationalities sharing common values work at Novartis companies.
Find out more about the company on the website www.novartis.ru and on the pages of accounts of
NovartisRussia and SandozRussia in social networks